| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
Animal experiments were performed to investigate therapeutic effects of alpha-2 adrenergic agonist-induced cardiac vagal activation on chronic heart failure. Ninety days survival was observed in doxorubicin-induced cardiomyopathy mice treated with dexmedetomidine or guanfacine. Because both alpha-2 adrenergic agonists did not improve 90 days survival in mice, several acute experimental studies using normal rats were added. These studies revealed that alpha-2 adrenergic agonists centrally suppressed cardiac sympathetic nerve activity but increased peripheral vascular resistance. Therefore, therapeutic benefits of alpha-2 adrenergic agonists on chronic heart failure may be dependent on the balance between sympatholytic effect and increased ventricular afterload in addition to cardiac vagal enhancement.
|
